


CLAIMS

What is claimed is:

- 5 1. A TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a TNF α inhibitor for use in method of treating rheumatoid arthritis, comprising
administering to a patient a therapeutically effective dose of a TLR7/8 inhibitor or a
pharmaceutically acceptable salt thereof, in combination with a therapeutically effective
dose of a TNF α inhibitor.

10

2. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TLR7 inhibitor is:



- 15 or a pharmaceutically acceptable salt thereof.

3. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use~~method~~ according to claim 1 wherein said TNF α inhibitor is etanercept or a biosimilar thereof.

20

4. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use~~method~~ according to claim 1 wherein said TNF α inhibitor is infliximab or a biosimilar thereof.

- 25 5. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use~~method~~ according to claim 1 wherein said TNF α inhibitor is certolizumab or a biosimilar thereof.

6. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination

with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TNF α inhibitor is golimumab or a biosimilar thereof.

7. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TNF α inhibitor is adalimumab or a biosimilar thereof.

8. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to Claim 1, wherein ~~said therapeutically effective dose of~~ said TLR7 inhibitor is to be administered in a therapeutically effective dose of from 0.1 to 100 mg per day.

9. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TLR7/8 inhibitor and said TNF α inhibitor are to be administered concurrently.

10. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TLR7/8 inhibitor and said TNF α inhibitor are to be administered sequentially.

11. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TLR7/8 inhibitor is to be administered prior to administration of said TNF α inhibitor.

12. The TLR7/8 inhibitor or a pharmaceutically acceptable salt thereof, in combination with the TNF α inhibitor for use ~~method~~ according to claim 1 wherein said TNF α inhibitor is to be administered prior to administration of said TLR7/8 inhibitor.

13. A polypeptide comprising amino acid residues 18-486 of SEQ ID NO:1.

14. The polypeptide of claim 13, wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:1.